Clinical Trial Update: Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of pembrolizumab in metastatic castration-resistant prostate cancer, with or without DNA damage repair defects; the study is completed an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, San Francisco | Conditions: Castration Resistant Prostatic Cancer, Metastatic Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-20